NDARECTALENEMA
Approved
Dec 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
MEDROL (methylprednisolone acetate) by Pfizer is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids. Approved for dermatomyositis, polymyositis, systemic lupus erythematosus and 4 more indications. First approved in 1977.
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEDROL is methylprednisolone acetate, a synthetic glucocorticoid administered as a rectal enema for anti-inflammatory and immunosuppressive effects. It is indicated for inflammatory and autoimmune conditions including systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, asthma, and dermatologic disorders. The drug works by modifying immune response and reducing inflammation across multiple organ systems.
$11KPart D
LOE ApproachingMinimal market presence with declining spending suggests a shrinking brand team focused on legacy product maintenance rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt retaining properties, are used in replacement therapy in adrenocortical deficiency states. Their synthetic…
Indications (7)
Worked on MEDROL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.